Letters sent to healthcare professionals in September 2017

Letters were sent in September about Dacogen (decitabine), Eperzan▼(albiglutide), ERWINASE, ReoPro (abciximab), and recombinant human erythropoietins.

In September 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

Article citation: Drug Safety Update volume 11, issue 3; October 2017: 5.

Published 26 October 2017